RxDoctor Payments Data

Barnard San Gabriel, MD

Internal Medicine · Munster, INNPI 1427269950

Payments from drug & device makers

$750in general payments, 2019–2025

Across 41 payments — averaging $18.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$106
  • Novo Nordisk$103
  • Coloplast$77
  • Boehringer Ingelheim$74
  • AstraZeneca$52
  • AbbVie$49
  • plus $289 from 12 others

What the payments were for

  • Food & beverage$67290%
  • Education$7710%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$750 in reported general payments places this provider in the 70th percentile of 1,747 internal medicine providers in Indiana.

See all internal medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$110,929
Medicare patients
308
Services billed
1,095

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide111$159,799
TrulicityDulaglutide49$99,372
MounjaroTirzepatide71$84,301
JardianceEmpagliflozin57$70,015
JanuviaSitagliptin Phosphate38$58,826
EliquisApixaban47$45,241
XareltoRivaroxaban27$44,401
RybelsusSemaglutide21$29,792
EntrestoSacubitril/Valsartan15$29,527
FarxigaDapagliflozin Propanediol24$25,284
Breo ElliptaFluticasone/Vilanterol37$18,162
Trelegy ElliptaFluticasone/Umeclidin/Vilanter22$18,086
Tresiba Flextouch U-100Insulin Degludec23$11,528
Humalog Kwikpen U-100Insulin Lispro22$11,028
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog27$10,253

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$103$189,591132 claims
Lilly USA, LLCTrulicity, Mounjaro$15$183,673120 claims
Boehringer IngelheimJardiance$74$70,01557 claims
MerckJanuvia$11$58,82638 claims
PfizerEliquis$106$45,24147 claims
Johnson & JohnsonXarelto$31$44,40127 claims
GSKBreo Ellipta, Trelegy Ellipta$12$36,24859 claims
AstraZenecaFarxiga$52$25,28424 claims
AbbVieSynthroid$49$2,34639 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,747 internal medicine providers in Indiana.

Other internal medicine in Munster

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →